Three million euros for European research initiative to develop new technology to regenerate the brain
Over the next four years, Helmholtz Munich participates in a European research consortium, aiming to develop an innovative technology that could boost the regeneration of neurons in diseases that currently have limited therapeutic options. The…
Featured Publication,
Molecular Targets and Therapeutics,
STB,
New method to investigate the structure and dynamics of challenging membrane proteins
Researchers created a new approach to reduce the complexity of the NMR experiments and facilitate the investigation of membrane protein systems of pharmaceutical importance.
MISATO Dataset: Transforming Drug Discovery with AI
A team led by Helmholtz Munich scientist Dr. Grzegorz Popowicz unveils the Molecular Interactions Structurally Optimized (MISATO) dataset, offering a transformative approach to training AI models for designing new drug molecules. MISATO represents a…
Transfer,
Molecular Targets and Therapeutics,
STB,
First Patient Administered New Drug for Brain Tumor Treatment
In an ongoing phase 1 clinical trial targeting malignant glioblastoma, the initial patient has received a dosage of a novel drug candidate, derived from an antibody originating at Helmholtz Munich. This innovative compound, coupled with a…
Identification of a key factor for splicing long introns
Mutations in FUBP1 cause defective gene regulation in glioma cells
Pre-mRNA splicing is an essential step in the maturation of mRNA in which introns are removed and the remaining exons are linked to create a mature mRNA as template for proteins.…
